Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Suma Ramadas, PhD
Medical Affairs

Matt Turner
Patient Affordability

Frank Burrell
Scientific Storytelling

David Linetsky
Point-of-Care Marketing

Paul Theisen
Patient Acquisition

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement